Key result
Novel RyR2 mutations in pediatric CPVT highlight the importance of genetic testing for timely management.
Case Report (n=2)
Highlights the importance of genetic testing for RyR2 mutations in children presenting with exertion-induced syncope to diagnose and manage CPVT.
Supports genetic testing for RyR2 in exertional syncope; hypothesis-generating and should not yet change practice.
Recurrent syncope during exertion or stress should be focused on catecholaminergic polymorphic ventricular tachycardia caused by ryanodine receptor 2 gene mutations. The genetic testing is a crucial tool in confirming the mutation of catecholaminergic polymorphic ventricular tachycardia. Early recognition of this disease, timely diagnosis of ryanodine receptor 2 gene mutations, and administration of appropriate pharmacological agents or ICD implantation are critical to ensure favourable clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Zou et al. (2026) conducted a case report in Catecholaminergic polymorphic ventricular tachycardia (n=2). Genetic testing was evaluated. Two novel ryanodine receptor 2 mutations were identified in children with catecholaminergic polymorphic ventricular tachycardia, highlighting the importance of genetic testing for timely management.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: